JMP Securities analyst Jason Butler raised the firm’s price target on Rezolute (RZLT) to $8 from $7 and keeps an Outperform rating on the shares following Q1 results. The Phase 3 trial for ersodetug in congenital hyperinsulinism continues to enroll patients and results remain on track for 2H25, the firm noted.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT: